Skip to main content

Advertisement

Figure 2 | Breast Cancer Research

Figure 2

From: Breast tumors from CHEK2 1100delC- mutation carriers: genomic landscape and clinical implications

Figure 2

Breast cancer (BC)-related survival differences in three sample sets divided on the basis of the CHEK2 1100delC signature. Expression levels of the CHEK2 1100delC-related genes divide breast tumors into groups of better and poorer prognosis. Significant differences in overall or disease-free survival were detected in Helsinki and Uppsala cohorts, whereas in the Stockholm cohort, the differences were more subtle. The difference between the curves was measured with the log-rank test.

Back to article page